Wednesday, June 28, 2017 3:42:10 PM
Still, VB-111 looks promising and I'm looking forward to the interim in Sept/Oct.
http://www.sciencedirect.com/science/article/pii/S111003621630036X
Table 3. Summarizes different agents used for the treatment of rGBM alone or in combination failed to achieve significant response in phase I/II/III trials.
Drug/Phase Type of drug
Verubulin/Phase II Microtubule destabilizer and Vascular disrupting agent
Erlotinib + temsirolimus/PhaseII Epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR)
Sunitinib/Phase II Inhibitor of several receptor tyrosine kinases
Fotemustine/Phase I; Phase II VEGF inhibitor with Nitrosurea
Enzastaurin/Phase II, Phase III Selective oral inhibitor of protein kinase Cß
Cediranib/Phase III [monotherapy or in combination with Lomustine] Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor
Dasatinib/Phase II Multitargeted tyrosine kinase inhibitor
Bosutinib/Phase II Kinase inhibitor of Src and Abl
Cilengitide/Phase II av integrin antagonist
CT-322/Phase II Inhibitor of VEGFR-2
Veliparib/Phase I PARP inhibitor
Pazopanib + Lapatinib/Phase II Antiangiogenic pazopanib; ErbB inhibitor lapatinib
Gimatecan/Phase II Lipophilic oral camptothecin analog
Nintedanib/Phase II Triple angiokinase inhibitor
Vandetanib/Phase II Multi targeted tyrosine kinase inhibitor
Patupilone/Phase II Natural microtubule-stabilizing cytotoxic agent
Vorinostat/Phase II; Romidepsin/Phase II Histone deacetylase (HDAC) inhibitor
TLN-4601/Phase II Ras-MAPK signaling pathway inhibitor
Aflibercept/Phase II VEGF Trap
Sagopilone/Phase II Lipophylic and synthetic analog of epothilone B
Rilotumumab/Phase II A fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF)
Imatinib + hydroxyurea/Phase II Protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase
Didemnin B/Phase II Natural product derived from the Caribbean Tunic inhibit all phases of the cell cycle
Induces rapid and wholesale apoptosis through dual inhibition of PPT1 and EEF1A1
KRN8602(MX2)/Phase II A novel morpholino anthracycline with capacity to cross BBB
Thalidomide/Phase II Putative inhibitor of angiogenesis
Paclitaxel/Phase II Enhances the polymerization of tubulin to stable microtubules
Cystemustine/Phase II Nitrosourea
Marimastat/Phase II Matrix metalloproteinase inhibitor
XR5000/Phase II Tricyclic carboxamide that intercalates DNA and inhibits both topoisomerase I and II
Gefitinib/Phase II; Erlotinib/Phase II Epidermal growth factor receptor tyrosine kinase inhibitor
Cloretazine/Phase II Novel alkylating agent belonging to 1,2-bis(sulfonyl)hydrazines class
Cetuximab/Phase II Anti EGFR monoclonal Antibody
Trabedersen/Phase II TGF-ß2 inhibitor
Bortezomib/Phase II Proteasome inhibitor
Convection-enhanced delivery (CED) of cintredekin besudotox (CB) was compared with Gliadel wafers (GW)/Phase III Nitrosurea in Wafer
Recent VBLT News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:05:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:19 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/29/2024 08:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:34:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:31:04 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/09/2024 08:01:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:40:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:36 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/01/2024 09:19:40 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/20/2024 09:01:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:18:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:12:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:06:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:04:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:30:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/19/2024 08:56:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/12/2024 12:44:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/11/2024 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2024 04:15:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2024 01:00:14 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM